about
High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection.Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP studyPopulation analysis of a 24-h paclitaxel infusion in advanced endometrial cancer: a gynaecological oncology group studyPancratistatin induces apoptosis in clinical leukemia samples with minimal effect on non-cancerous peripheral blood mononuclear cells.Translational considerations for cancer nanomedicine.Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation.Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trialCarotid artery infusions for pharmacokinetic and pharmacodynamic analysis of taxanes in mice.Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice.A critical review of lipid-based nanoparticles for taxane delivery.Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq) and paclitaxel.Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancerCYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinomaPharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate.Paclitaxel: a review of adverse toxicities and novel delivery strategies.Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy.Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion.Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.Novel dietary lipid-based self-nanoemulsifying drug delivery systems of paclitaxel with p-gp inhibitor: implications on cytotoxicity and biopharmaceutical performance.Albendazole sensitizes cancer cells to ionizing radiation.In vivo evaluation of novel chitosan graft polymeric micelles for delivery of paclitaxel.Differential activity of caspase-3 regulates susceptibility of lung and breast tumor cell lines to Paclitaxel.Bcl-2/Bcl-xL inhibitor ABT-737 sensitizes pancreatic ductal adenocarcinoma to paclitaxel-induced cell death.Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer.Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity?Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysisIncreased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study.Aqueous N,N-diethylnicotinamide (DENA) solution as a medium for accelerated release study of paclitaxel.ET(B) receptor agonist, IRL 1620, does not affect paclitaxel plasma pharmacokinetics in breast tumour bearing rats.Synthesis of poly(1,2-glycerol carbonate)-paclitaxel conjugates and their utility as a single high-dose replacement for multi-dose treatment regimens in peritoneal cancer.
P2860
Q25257484-80F6C496-1D0B-4412-A4DE-590C54F39F8EQ28359347-EC84655C-8A28-4450-974F-776DA49936F1Q30443910-44F99BFF-4548-4F17-BE67-40DFDBA1B228Q33753516-DF27FB9B-A1D0-44BC-8E32-7D8867DFB7B2Q34065785-C314A23F-21C8-4EFD-9107-D309E10CFAB7Q34871917-5B2028FB-267D-4904-AA15-C079D063A5F6Q35037971-A03436AC-B3BC-49CC-8BFF-E30B0435CAA3Q35158424-43ADA70F-82BE-4AE9-A352-86E90E8CCAA5Q35166688-FBD31CF4-7C1C-4C6F-9A63-108731B36875Q36135012-85A321B9-543B-43E0-BA75-332B83BC7D32Q36360764-D9177394-C293-4DE5-B329-7A039C780D90Q36621462-DACC8C47-4A12-439C-82C8-9E1B232251D8Q36623452-3F564203-F0EC-4C23-A014-C3FFE75EBF52Q36657755-78611AA8-D4EF-40C6-9F82-C9A43AEDBCEBQ36885663-507B4557-A0F5-4913-A1CC-23DA18690199Q36920312-EF2C7B08-5024-475F-A8D8-533C341780BDQ36945032-88420863-1DE6-450B-BA73-24087AEDB879Q37119643-C0E4ADF3-B321-4AD7-885C-E90B46F9E3FEQ37468177-14521689-C328-4225-B5BD-AA3229DCFF19Q38726616-1EC9A2C7-9E5A-45C2-B3C2-72BFDC36D3BBQ38850605-7F6B9496-6A78-431F-B09D-97E700069E93Q38856512-64F9CD86-54AA-4B8C-8140-9A5BD850529CQ39441389-718FE7FD-4D50-4241-B33E-925C800D1A0FQ39644963-AE33AD3F-68F6-4073-B249-ED3476E9DA3DQ39880418-466D6D39-7E7A-4D57-814B-889D62826106Q40977884-2549C6C5-895B-4430-B30D-C3A210DE94B3Q41897007-A55E9B65-09F7-495E-955F-2F7FE84E7E90Q42225639-41D9B1BD-9D9A-4099-AF6E-C6B98EB5101DQ42239440-92D90B70-76A9-43D3-ADD6-CE1C2509DB21Q44019385-26BC7CA4-D861-4205-A9B5-928E2A5C17C3Q44948064-0F360882-471E-4AF3-BBA8-F2667E46E52DQ46559935-1C1084C8-C6F8-48CD-A27E-7D617C726D2BQ52606027-92463E3F-82E1-45D3-A4E7-F15BF1D955C3
P2860
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Clinical pharmacokinetics of paclitaxel.
@en
type
label
Clinical pharmacokinetics of paclitaxel.
@en
prefLabel
Clinical pharmacokinetics of paclitaxel.
@en
P1476
Clinical pharmacokinetics of paclitaxel.
@en
P2093
D S Sonnichsen
M V Relling
P304
P356
10.2165/00003088-199427040-00002
P577
1994-10-01T00:00:00Z
P6179
1053348338